REPL logo

REPLIMUNE GROUP INC

REPLNASDAQ
🏆 #2365 by market capEarnings Nov 4US Equity
$170.69▲ $2.75 (+1.61%)
Simulated price
🔔
Track REPL
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.6%
7d▲ 1167.2%
14d▲ 1210.5%
30d▲ 1001.6%
ytd▲ 1657.9%
1y▲ 3828.4%
🏦Market Cap
$1.18B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
68
Fair

Trading Snapshot

Day Range
$168.84 – $172.58
52-Week Range
$1.50 – $16.33
Volume
$5.10B
Avg Volume
$6.27B
Shares Outstanding
84.0M
Next Earnings
Nov 28, 2026

Fundamentals Snapshot

Annual Revenue
$208M
Last Q Revenue
$49M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-3.16
Dividend Yield
—
Dilution (1yr)
+5.1%

Why Investors Own REPL

  • ✓High-growth profile — revenue up -1.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 58% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

REPL logo

REPLIMUNE GROUP INC

REPL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$320M▲ +22.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$285M▲ +43.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
96.9M▲ +5.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$73M▲ +$27M YoY
StockOtter · stockotter.space

About REPLIMUNE GROUP INC

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$218.53
▲ +28.0% Upside
High Target$240.80
Low Target$194.33
Based on 39 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

REPLIMUNE GROUP INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift REPL price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

REPLIMUNE GROUP INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.